跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PRALUENT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PRALUENT
Authorized
STANDARD
PRALUENT
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2bb1e55aa1a0e184
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
2bb1e55aa1a0e184
Drug Approval Canada Name
PRALUENT
Product Name
PRALUENT
Status
Cancelled Post Market
Status Date
2021-03-04
Original Market Date
2016-08-13
Din
02453762
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
24:06.24
Atc Original
C10AX14 ALIROCUMAB
Atc Name
c 10 ax 14
Aig Number
0158030002
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
ALIROCUMAB
150 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2bb1e55aa1a0e184
Type
Standard
Back to Health Canada Approvals